Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by Algert Global LLC

Algert Global LLC grew its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 22.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 205,988 shares of the company's stock after purchasing an additional 37,927 shares during the period. Algert Global LLC owned approximately 0.30% of Arvinas worth $3,949,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in ARVN. KBC Group NV boosted its stake in shares of Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after acquiring an additional 1,255 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Arvinas during the fourth quarter worth $171,000. Teacher Retirement System of Texas grew its holdings in Arvinas by 19.0% in the fourth quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company's stock valued at $274,000 after purchasing an additional 2,280 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Arvinas by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company's stock valued at $279,000 after buying an additional 1,367 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Arvinas during the 4th quarter worth $332,000. Hedge funds and other institutional investors own 95.19% of the company's stock.

Arvinas Stock Performance

ARVN traded down $0.20 on Friday, reaching $6.61. 1,632,477 shares of the company's stock were exchanged, compared to its average volume of 1,288,010. The company has a market cap of $482.47 million, a price-to-earnings ratio of -2.39 and a beta of 2.21. Arvinas, Inc. has a twelve month low of $5.94 and a twelve month high of $37.38. The company's 50 day moving average is $8.65 and its 200-day moving average is $16.82.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $1.14 EPS for the quarter, beating analysts' consensus estimates of ($0.93) by $2.07. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the prior year, the firm posted ($0.97) EPS. The business's revenue was up 646.2% on a year-over-year basis. Sell-side analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Barclays dropped their target price on shares of Arvinas from $32.00 to $16.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. TD Cowen cut shares of Arvinas from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Truist Financial reaffirmed a "hold" rating and issued a $11.00 target price (down previously from $21.00) on shares of Arvinas in a research note on Monday, May 5th. HC Wainwright dropped their price target on Arvinas from $81.00 to $24.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Finally, Morgan Stanley decreased their price objective on Arvinas from $12.00 to $11.00 and set an "equal weight" rating on the stock in a research note on Friday. Eight analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Arvinas currently has a consensus rating of "Moderate Buy" and an average price target of $20.91.

Insider Buying and Selling at Arvinas

In related news, insider Ian Taylor sold 9,020 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $16.71, for a total transaction of $150,724.20. Following the transaction, the insider now directly owns 159,121 shares of the company's stock, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Noah Berkowitz sold 8,658 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total transaction of $74,372.22. Following the completion of the sale, the insider now directly owns 110,023 shares of the company's stock, valued at $945,097.57. This trade represents a 7.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,230 shares of company stock valued at $769,402 over the last three months. 5.23% of the stock is owned by company insiders.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.